Six cases positive for anti-centromere antibodies with ulcer and gangrene in the extremities

British Journal of Rheumatology

Volumn 36, Issue 8, 1997, Pages 889-893

  Takahashi, M ^a   Okada, J ^a   Kondo, H ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti centromere antibody; Gangrene; Raynaud's phenomenon; Scleroderma

Indexed keywords

AUTOANTIBODY;

ADULT; AMPUTATION; ARTICLE; CENTROMERE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FINGER; GANGRENE; HUMAN; LEG ULCER; MALE; ONSET AGE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SKIN CALCIFICATION; SKINFOLD; SYNDROME CREST; SYSTEMIC SCLEROSIS; TOE;

EID: 0030770503     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.8.889     Document Type: Article

References (18)

1. Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 1992;35:688-93.
2. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine 1982;59:393-408.
3. Fritzler MJ, Hart DA. Prolonged improvement of Raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy. Arthritis Rheum 1990;33:274-6.
4. Jarrett PEM, Morland M, Browse NL. Treatment of Raynaud's phenomenon by fibrinolytic enhancement. Br Med J 1978;2:523-5.
5. Reilly IAG, Roy L, Fitzgerald GA. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br Med J 1986;292:1057-9.
6. Seibold JR, Harris JN. Plasma b-thromboglobulin in the differential diagnosis of Raynaud's phenomenon. J Rheumatol 1985;12:99-103.
7. Wigley FM, Wise RA, Malamet R, Scott TE. Nicardipine in the treatment of Raynaud's phenomenon: dissociation of platelet activation from vasospasm. Arthritis Rheum 1987;30:281-6.
8. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Arthritis Rheum 1991;34:978-83.
9. Goldman JA. Anticentromere antibody in patients without CREST and scleroderma: association with active digital vasculitis, rheumatic and connective tissue disease. Ann Rheum Dis 1989;48:771-5.
10. Barr WG, Robinson JA. Systemic sclerosis and digital gangrene without scleroderma. J Rheumatol 1988; 15:875-7.
11. Herric AL, Heaney M, Hollis S, Jayson MIV. Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia. Ann Rheum Dis 1994;53:540-2.
12. Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 1980; 77:1627-31.
13. Kallemberg CGM, Pastoor GW, Wouda AA. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis 1982;41:382-7.
14. McCarty GA, Rice JR, Bembe ML, Barada FA Jr. Anticentromere antibody Clinical correlations and association with favorable prognosis in patients with scleroderma variants. Arthritis Rheum 1983;26:1-7.
15. Bernstein RM, Callender ME, Neuberger JM, Hughes GRV, Williams R. Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis 1982;41:612-4.
16. Steen VD, Powell DL, Medsger TJ. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
17. Oddis CV, Eisenbeis CHJ, Reidbord HE, Steen VD, Medsger TJ. Vasculitis in systemic sclerosis: association with Sjögren's syndrome and the CREST syndrome variant. J Rheumatol 1987;14:942-8.
18. Kaheleh MB. Vascular disease in scleroderma: endothelial T lymphocyte-fibroblast interactions. Rheum Dis Clin North Am 1990;16:53-73.